Abstract
Positron Emission Tomography (PET) can be used to assess changes of endogenous neurotransmitters induced by pharmacological or physiological challenges and has been successfully applied to the study of the dopaminergic system, and, to a lower extent, to the serotonergic, opioid and cholinergic systems. This review first introduces the principles underlying the assessment of fluctuations of endogenous neurotransmitters with PET and then summarizes the main results obtained for dopamine, with emphasis on clinical studies. The studies of serotonin, opioid peptides, acetylcholine and the few studies dealing with other neurotransmitters (GABA, glutamate) are subsequently reviewed. In conclusion the chances of successfully imaging endogenous neurotransmitters with PET as well as possible trends for the future are discussed.
Keywords: Binding potential (BP), competition model, endogenous neurotransmitter (EN), internalization model, pharmacological challenge, positron emission tomography (PET), serotonin, opioid peptides, acetylcholine, Parkinson's disease, amphetamine, epidepride, methylspiperone, fallypride, Antagonist Tracers
Current Psychopharmacology
Title: Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies
Volume: 1 Issue: 1
Author(s): Giampaolo Tomasi
Affiliation:
Keywords: Binding potential (BP), competition model, endogenous neurotransmitter (EN), internalization model, pharmacological challenge, positron emission tomography (PET), serotonin, opioid peptides, acetylcholine, Parkinson's disease, amphetamine, epidepride, methylspiperone, fallypride, Antagonist Tracers
Abstract: Positron Emission Tomography (PET) can be used to assess changes of endogenous neurotransmitters induced by pharmacological or physiological challenges and has been successfully applied to the study of the dopaminergic system, and, to a lower extent, to the serotonergic, opioid and cholinergic systems. This review first introduces the principles underlying the assessment of fluctuations of endogenous neurotransmitters with PET and then summarizes the main results obtained for dopamine, with emphasis on clinical studies. The studies of serotonin, opioid peptides, acetylcholine and the few studies dealing with other neurotransmitters (GABA, glutamate) are subsequently reviewed. In conclusion the chances of successfully imaging endogenous neurotransmitters with PET as well as possible trends for the future are discussed.
Export Options
About this article
Cite this article as:
Tomasi Giampaolo, Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies, Current Psychopharmacology 2012; 1(1) . https://dx.doi.org/10.2174/2211556011201010029
DOI https://dx.doi.org/10.2174/2211556011201010029 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Gene Therapy for Ocular Neovascularization
Current Gene Therapy Approaching Inherited Disease on a Genomic Scale
Current Genomics Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Nutritional Control, Gene Regulation, and Transformation of Vascular Smooth Muscle Cells in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets The Effect of Claudin-5 Overexpression on the Interactions of Claudin-1 and -2 and Barrier Function in Retinal Cells
Current Molecular Medicine The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising
Current Pharmaceutical Design Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma
Current Molecular Medicine Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer
Current Drug Targets Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Sphingolipids in Genetic and Acquired Forms of Chronic Kidney Diseases
Current Medicinal Chemistry Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design A Transcriptomics Study to Elucidate the Toxicological Mechanism of Methylmercury Chloride in a Human Stem Cell Based In Vitro Test
Current Medicinal Chemistry Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Senescence and Cell Death Pathways and Their Role in Cancer Therapeutic Outcome
Current Medicinal Chemistry Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery